In Japan, Expanding a Label Is What Triggers the Price Cut
Dupixent, Nucala and Vyvdura were all cut after adding an indication. In Japan the trigger for a price cut is the drug reaching more patients.
Pricing & Reimbursement
Australia Cannot Settle Its Device Price Fight While the Service Sits Inside the Price
Both sides are fighting over a number nobody can produce. The evaluation went underneath them and named the reason: the service is inside the price.
Korea Cleared Two Diagnostics on One Day, and Both Remove a Specialist
Nobody gained insurance access. Designation is the gate before the negotiation. The real story is that both lead technologies remove a specialist.
CMS Opened a Same-Day Coverage Lane for Devices and Closed the Payment Route Underneath It
CMS Opened a Same-Day Coverage Lane for Devices and Closed the Payment Route Underneath It
Washington Narrowed the Childhood Schedule, and the Insurer Backstop Quietly Stopped Being One
Washington Narrowed the Childhood Schedule, and the Insurer Backstop Quietly Stopped Being One
NICE Backed Acalabrutinib and Venetoclax Without Obinutuzumab, and the Omission Is the Decision
AMPLIFY tested acalabrutinib and venetoclax with and without obinutuzumab. NICE recommended the doublet, which is a decision about infusions.
Lilly’s Volume Rose 60%, Its Realized Prices Fell 13%, and the Top of Its EPS Range Came Down
QuickAccess read/Cardio-Metabolic/Peptide Lilly’s Volume Rose 60%, Its Realized Prices Fell 13%, and the Top of Its EPS Range Came Down Athithi Verma· 6 August 2026· 3 min read· Synopulse Eli Lilly reported Q2 2026 revenue of $23.0 billion, up 48%, driven by a 60% increase in volume and partially offset by a 13% decrease in … Read more
Dr. Reddy’s Developed, Made and Filed the Rituximab. Fresenius Only Sells It.
Fresenius describes an end to end biopharma business. Dr. Reddy’s developed, made and filed this rituximab. Fresenius is only the channel.
The 340B Rebate Pilot Is Back at Under 5.5% of Sales, Rebuilt to Survive the Court That Killed It
HRSA restarted the 340B rebate pilot at under 5.5% of sales, wrapped in 21 pages of answers to the court that vacated the first one.
Approval Is Day One. In Canada, Patients Wait Another Five Hundred Days.
A Canadian government task force counted the wait for public drug coverage: 200 days for HTA, 195 for price negotiation, then up to 219 more per province.